Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
About NOW
Its a best-case scenario
The increased secretion of fluid into the intestines may exacerbate this effect
The ANTHEM-UC study (NCT06049017) is a Phase 2b multicenter, placebo-controlled, dose-ranging RCT evaluating three once-daily oral doses of icotrokinra versus placebo in 252 adults with moderately to severely active UC who had inadequate response or intolerance to conventional therapy, prior biologics, or JAK inhibitors, with the primary endpoint being clinical response at Week 12 (defined as 30% and 2-point decrease in mMS with rectal bleeding improvement)
In people with hormonal fluctuations or cervical issues, this could trigger light bleeding
Practical issues in high-speed cell sorting
US$ 26.68
.png)
US$ 29.07
US$ 26.97
US$ 21.35
US$ 22.65
US$ 24.89
